Abstract: A pigment having at least two layers according to the following structure (I), where C is an internal pigment core of formula [Mx(O)y(OH)z]; where MX=TiIV, ZnII, ZrIV, SnIV, FeII, FeIII, SnII, CrVI, or MnII; x=2, 3 or 4; and (y/2+z)=x; A is a plant polyphenol having an active-redox, radical scavanger behaviour and at least two chelating moieties and B is an outer hydrophobic layer consisting in an anionic surfactant, and where Ma and Mb denotes, each independently, Mq+=Ca2+, Zn2+, Ti4+, Si4+, Al3+, Sn4+, Mg2+, or Sr2+; and a=0 or 1; b=1; q=2, 3 or 4.

Abstract: The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis.

Abstract: A stable, sporicidal hand sanitizer formulation is described. The formulation is a lotion including peracetic acid and one or more short chain alcohols. The lotion demonstrates an extended presence of active PAA and is capable of achieving a total kill of a bacteria in less than about 10 minutes contact time and more particularly, in about 2 minutes contact time.

Abstract: The present disclosure generally relates to personal care compositions and personal care products. More particularly, the disclosure relates to personal care compositions and personal care products that impart perceivable aesthetic benefits of increased softness, quietness and drapability to the skin or hair of a user. To achieve the perceivable aesthetic benefit, a protonated skin aesthetic agent selected from fatty acids, fatty alcohols, fatty acid derivatives, fatty alcohol derivatives, and/or combinations thereof, may be incorporated into the personal care compositions and personal care products. To produce the liquid composition, a deprotonated skin aesthetic agent is first provided. The deprotonated skin aesthetic agent is added to an aqueous liquid solution. The aqueous liquid solution is then acidified with an acidifying agent to protonate the deprotonated skin aesthetic agent. Finally, the aqueous liquid solution is incorporated onto a wipe substrate.

Abstract: This invention relates to agricultural compositions that find particular use as a fungicide composition. The fungicide composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal activity; however, when combined with a fatty acid, the organic acid functions as a potent synergist for the fatty acid as a fungicide. Additionally, the fungicide composition can include other components such as emulsifiers, adjuvants, surfactants and diluents. The fungicide composition significantly reduces or prevents the fungal infection of cash crops including vegetables, fruits, berries, seeds, grains and at higher application rates, can also be used as a harvest aid or desiccant for harvested crops such as potatoes.

Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.

Abstract: The present invention relates to a thixotropic pharmaceutical composition in which the viscosity is changed due to external mechanical stress applied so that isothermal and continuous gel/sol/gel transition occurs. The thixotropic pharmaceutical composition includes a pharmacologically active substance, a biocompatible thickener having a predetermined thixotropic property, and optionally a hydrophilic thickener. The viscosity of the composition is relatively rapidly changed within a predetermined range. Accordingly, it is easy to measure the amount of drugs to be administered, it is possible to administer a precise amount of drugs to a patient, the compliance of a patient with dosage of drugs is high, and it is easy to produce the composition.

Abstract: The invention relates to composition and related therapeutic methods including at least one antihyperthyroid drug formulated for transdermal administration. Because the formulation is formulated for transdermal administration, the formulation is easier to administer than existing formulations which are administered orally to animals. Issues surrounding transdermal administration versus oral administration have also been resolved allowing the agent to remain stable during storage and retain a high level of efficacy.

Abstract: A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

Abstract: Coated particles of metal (such as calcium) silicate that exhibit excellent odor neutralization and sebum absorption properties when present within certain cosmetic and/or personal care formulations and suspensions are provided. Uncoated calcium silicate exhibits a high pH level that may have a deleterious effect upon such cosmetic and/or personal care compositions, thereby rendering the overall composition ineffective for its intended purpose, particularly if the calcium silicate is present in its usual state at high loading levels. Alternatively, if certain materials present within personal care compositions exhibit a sufficiently low pH level, the effectiveness of such calcium silicates may be compromised as well.

Abstract: The present invention relates to a lubricant granulate prepared using a hot melt granulation process, or thermal-heat process. The lubricant granulate is useful in facilitating the use of higher concentrations of lubricant than typically possible in pharmaceutical compositions. Also provided are pharmaceutical compositions comprising the lubricant granulate. Such pharmaceutical compositions can contain bisphosphonic acid as the active ingredient and can be suitable for oral administration. The present invention also provides a hot melt process for preparing the lubricant granulate for subsequent use in pharmaceutical compositions.

Abstract: With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the water-swellable gel-forming layers 12 are provided, either directly or via intermediate layers, on the both faces of the drug-containing layer 11.

Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Abstract: Method of inhibiting discoloration in agents by incorporating iodide salt(s), preferably calcium, potassium and/or sodium iodides into the formulation of those agents. The method is particularly suited for agents comprising vanillin and/or vanillin derivatives, wherein vanillin and/or vanillin derivatives are components of a fragrance mixture and the agents are washing and cleaning agents or cosmetics agents.

Abstract: The present invention provides compositions and clear oil-in-water microemulsion containing up to 80% w/w of an oil, a surfactant system, a w/w oil/surfactant system ratio between 1 and 3, and a solubilizing-aid ingredient which is not a surfactant neither a VOC compound, the latter being present in an amount sufficient to ensure that the ratio oil/(surfactant+solubilizing aid) is comprised between 0.1 and 5. The present invention concerns also the articles and products associated the compositions and microemulsions, and the methods to manufacture them.

Abstract: The invention relates to soap based liquid body and facial wash compositions. Using high solvent, low water compositions and incompletely neutralized fatty acid to help structure the compositions, all in combination with modified benefit agents, enhanced deposition of make-up agents is achieved.

Abstract: Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes.

Abstract: The present invention relates to a new lyophilized pharmaceutical composition capable of adhering to oral mucosal tissue for an extended period of time for delivering active pharmaceutical ingredient through the oral mucosal tissue using transmucosal absorption.

Abstract: The present invention relates to a gel composition useful for skin care and protection comprising up to 80% w/w Dead Sea water (or similarly constituted water), solubilizers, gelling agents or viscosity modifiers and deionized water to complete up to 100%. Preferably, the composition is a clear liquid gel. The gel optionally comprises hydrophobic and/or hydrophilic active agents. In the composition of the present invention the hydrophobic active agents may be vegetable oils, free fatty acids or vitamins, or any combination thereof and the hydrophilic active agent may be humectants, ?-hydroxy acids, anti irritant agents, plant extracts, moisturizing agents or hydrolyzed plant proteins or any combination thereof. The gel may further comprise antioxidants and fragrances.

Abstract: The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels.

Abstract: Disclosed herein are compositions and methods useful for the delivery of compounds across the blood brain barrier. Nanoparticles comprising lipids, such as brain lipids, are used to encapsulate drugs and to facilitate drug delivery to the brain.

Abstract: The invention relates to the novel use of ergothioneine and preferably, L ergothioneine, as a nutritional additive and preservative in foods, medicines, and/or beverages. According to the invention, the powerful antioxidant ergothioneine was found to be very stable over time in and to have no deleterious effects on taste or consistency of food and beverages even when stored, over a period of several years. In a preferred embodiment, ergothioneine may be used as a replacement for all or part of the antimicrobial/preservative sulfur dioxide or other sulfites traditionally used in the wine making process.

Abstract: There is provided an emulsion composition for therapeutic administration comprising: (a) at least one mono-(electron transfer agent) phosphate derivative; (b) at least one di-electron transfer agent phosphate derivative; wherein the amount of transfer agent phosphate derivatives is no less than equimolar to the amount of di-electron transfer agent phosphate; and (c) a suitable carrier.

Abstract: The present invention provides propyl phenoxy ether compounds and pharmaceutically acceptable salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same. The delivery agents of the present invention are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other routes of administration to animals.

Abstract: The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.

Abstract: The present invention is directed to the provision of pharmaceutical compositions such as multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy preservative efficacy requirements in the United States and/or Europe. The compositions include sorbate or a non-polymeric diquaternary ammonium compound for enhancing preservation efficacy. Further, the compositions typically have relatively low ionic strengths to assist in maintaining such efficacy.

Abstract: An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.

Abstract: Methods for controlling surface topography and binding reactivity in functionalized lipid layers, including in the form of liposomes, using pH-dependent processes. During direct cell-to-cell communication, lipids on the extracellular side of plasma membranes reorganize, and membrane associated communication-related molecules co-localize. At co-localization sites, sometimes identified as rafts, the local cell surface topography and reactivity are altered. Integration of these processes on nanometer-sized lipid vesicles used as drug delivery carriers would precisely control their interactions with diseased cells minimizing toxicities. Included are pH-dependent processes on functionalized lipid bilayers demonstrating reversible sharp changes in binding reactivity within a narrow pH window. Cholesterol enables tuning of the membrane reorganization to occur at pH values not necessarily close to the reported pKa's of the constituent titratable lipids.

Abstract: Composition for the implementation of a therapeutic method for the human or animal body, comprising a fatty phase (O) and an aqueous phase (W), in the form of an 5 emulsion of the water-in-oil (W/O) type, in which said aqueous phase (W) comprises at least one hydrosoluble active ingredient, characterized in that said composition has a viscosity, measured at 25° C. in a 250-cm3 beaker having a diameter of about 7 cm, using a Brookfield LVT viscosimeter equipped with a No. 2 spindle turning at a speed of 30 or 60 revolutions pre minute, of less than or equal to 10 [sic] 2000 mPas, and preferably less than 200 mPas.

Abstract: The present invention provides preservative compositions suitable for replacing, partially or in totality, conventional preservatives in skin care emulsions and heavy duty hand cleansers comprised of alternative molecular compounds than found in conventional preservative formulations. The preservative formulation for skin care formulations includes a fatty acid and/or ester of fatty acid present in a concentration from about 0.01 wt./wt. % to about 90 wt./wt. % of the formulation, one or more alcohols in a concentration from about 0.01 to about 60 wt./wt. % of the formulation, and a chelating agent present in a concentration from about 0.01 to about 20 wt./wt. % of the blend.

Abstract: The present invention relates to silicone modified fatty carboxylic acid compounds. More specifically, the present invention relates to low molecular weight, i.e., short chain, silicone modified fatty carboxylic acids, their use and method of making same. The present invention provides silicone compounds partially derived from natural products for use in cosmetic formulations.

Abstract: The present invention relates to compositions for transdermal administration of a therapeutic agent for providing a systemic therapeutic effect. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., wherein transdermal administration of the therapeutic agent may be either rapid or sustained.

Abstract: The present inventions provide various embodiments of medical devices coated with a therapeutic coating comprising a mTOR targeting compound and a calcineurin inhibitor, and methods of applying said coatings. In various aspects, the therapeutic coating comprises a bio-absorbable carrier component at least partially formed of a cellular uptake inhibitor and a cellular uptake enhancer, a mTOR targeting compound and a calcineurin inhibitor. In various aspects, the present invention provides for controlled delivery, which is at least partially characterized by total and relative amounts of a cellular uptake inhibitor and cellular uptake enhancer in a bio-absorbable carrier component.

Abstract: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.

Abstract: A delivery system for inclusion in an edible composition is formulated to have at least one active component encapsulated within an encapsulating material, whereby the delivery system has a tensile strength suitable for delivering the active component at a desired release rate.

Abstract: The present invention relates to novel pesticide compositions in the form of a gel material or a solid material which are suitable for combating arthropod pests, in particular insects. The pesticide composition in the form of a gel or solid contains i) 0.001 to 50% by weight of at least one pesticide compound which is effective against arthropod pest, ii) 0.5 to 20% by weight of at least one superabsorbent polymer P having an absorption capacity for deionised water of at least 100 g per 1 g of polymer P, and iii) 5 to 94.5% by weight of at least one filler material different from water, and iv) 5 to 94.5% by weight of water, wherein the % by weight are based on the total weight of the composition.

Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Abstract: There is provided is an adjuvant/dispersant for pesticide formulations (among other formulated uses) comprising at least one dialkyl alkanolamine such as dimethyl ethanolamine, at least one derivative thereof, or a combination thereof. Pesticide compositions comprising a pesticide, such as glyphosate, and the adjuvant/dispersant of the present technology and methods for enhancing the effectiveness of the pesticide, such as glyphosate, in an aqueous composition through the addition of the adjuvant/dispersant of the present technology are also disclosed. Solid pesticidal formulations comprising a pesticidal active ingredient and the adjuvant/dispersant of the present technology are also provided.

Abstract: The present invention relates to compositions for transdermal administration of therapeutic agents for providing a local and sustained therapeutic effect, wherein the extent of systemic administration can be controlled. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., for use in the treatment of pain and/or inflammation or administration of a local anaesthetic, wherein transdermal administration of the therapeutic agent may be either rapid or sustained.

Abstract: The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents.

Abstract: The present invention provides a novel rapid-melt pharmaceutical composition comprising a binder, a super emulsifier, a diluent/bulking material; and an active ingredient. The present invention also provides a rapid-melt bead composition comprising a binder having a melting point from about 20 to about 90° C., an emulsifier; a diluent/bulking material; and an active ingredient. Further, the present invention provides a chew tablet composition comprising a binder; an emulsifier having a melting point of greater than about 40° C.; a diluent/bulking material; and an active ingredient. Methods of making the disclosed compositions are also described.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: Disclosed is a perfume composition having a fragrance like that of green tea flowers. The perfume composition contains artificial synthetic substance trans-4,8-dimethyl-1,3,7-nonatriene or lilac alcohol, in addition to the main fragrant components of green tea flowers, analyzed by an SPME method or a solvent extraction method, and thus has a fragrance like that of the characteristic fragrance of green tea flowers and, at the same time, has high preference.

Abstract: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Abstract: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.

Abstract: A lecithin organogel (“LO”) operates as a transdermal pharmaceutical delivery composition. In particular, the lecithin organogel comprises an internal oil phase containing oil-in-water (“O/W”) and water-in-oil (“W/O”) emulsifiers, and an aqueous phase comprising inorganic and organic hydrocolloids. The lecithin organogel may contain up to 80% additive ingredients, including biocompatible surfactants, nonpolar solvents, saturated fatty alcohols, moisturizers, preservatives or antimicrobials, and chelating agents.

Abstract: A composition comprising from about 1 weight part to about 10 weight parts a saturated carboxylic acid having from 2 to about 20 carbon atoms; from about 0.1 weight parts to about 10 weight parts an antifungal compound; and from about 80 weight parts to about 99 weight parts skin-penetrating gel; wherein the saturated carboxylic acid, the antifungal compound, and the skin-penetrating gel together comprise 100 weight parts. In a particular example of the composition, the saturated carboxylic acid having from 2 to about 20 carbon atoms is acetic acid; and the antifungal compound is thymol. A method of treating onychomycosis in a patient, comprising applying the composition. The method provides a safe, effective treatment of onychomycosis.

Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.

Abstract: The invention relates to dispersions comprising water, lipophilic phase and emulsifier, characterized in that the emulsifier is present in an amount of less than or equal to 3% by weight based on the total weight of the dispersion, and in that the emulsifier comprises at least one acylglutamate. The dispersions of the invention are suitable for cosmetic and/or pharmaceutical preparations.

Abstract: An object of the present invention is to provide a nucleic acid delivery carrier composition of low toxicity and high safety, the carrier composition, when used to administer a nucleic acid such as an siRNA into an animal-derived cell or organism, being capable of delivering efficiently the nucleic acids into the cells while protecting it from being degraded; and a nucleic acid deliver composition containing the carrier and a nucleic acid. The carrier composition for delivery of a nucleic acid is prepared by mixing (A) a cationic lipid having a steroid skeleton with (B) a tertiary ammonium salt-type cationic lipid. The nucleic acid delivery composition is prepared by mixing the nucleic acid delivery carrier with a nucleic acid.